Edesa Biotech, Inc.

NASDAQ:EDSA

Biotechnology

Healthcare
$5.75 +1.31%

+$0.09 today

Market cap
$55.39M
Beta
1.07
P/E (TTM)
-5.5
EPS (TTM)
-$1.27
52W Low $0.72High $20.32

Volume 0.07M

Average 0.62M

EDSA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Edesa Biotech, Inc.NASDAQ: EDSA

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 8.25M shares rose 55.6% year over year, behind the +101.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 3.5% from the prior quarter. Over 3 fiscal years it compounded at +39.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +55.6% toward the trailing-twelve-month pace of +101.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
8.25M+3.5% QoQ
Last fiscal yearSep 2025
5.68M+77.5% YoY
LTMMar 2026
7.58M+101.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+55.6%——
1 year+77.5%——
3-year CAGR+39.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
5.68M USD
Year-over-year change
+77.5%
4-year CAGR
+34.7%

Weighted Avg Shares (Diluted) vs competitors

How EDSA compares with its peers on the latest reported figures

  • EDSA's LTM Mar 2026 weighted avg shares (diluted) of 7.58M shares is the lowest of the 2 companies compared; the peer median is 12.86M shares.
  • Its year-over-year change of +101.1% is the lowest of 2, against a peer median of +976.2%.
  • Over three fiscal years its annual growth of +39.4% compares with a peer median of +164.8%.
EDSA Competitors Peer median
Weighted Avg Shares (Diluted) for EDSA and competitors
Company Period LTM YoY 3-year CAGR
DWTXDogwood Therapeutics, Inc.LTM Mar 202612.86M +976.2%+164.8%
EDSAEdesa Biotech, Inc.LTM Mar 20267.58M +101.1%+39.4%
Peer median (excluding EDSA) 12.86M+976.2%+164.8%

Competitors are the stored peer set for EDSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00000
Cost of Revenue118.79K118.19K183.47K186.05K119.27K
Gross Profit(118.79K)(118.19K)(183.47K)(186.05K)(119.27K)
Gross Margin—————
Research & Development17.95M13.34M4.79M2.88M3.67M
Selling, General & Admin5.73M5.04M4.43M4.13M4.24M
Operating Expenses23.68M18.37M9.22M7.01M7.79M
Depreciation & Amortization118.79K118.19K183.47K186.05K119.27K
EBITDA(13.22M)(17.43M)(8.19M)(5.98M)(7.07M)
EBITDA Margin—————
Operating Income(23.68M)(18.37M)(9.22M)(7.01M)(7.91M)
Operating Margin—————
Interest Income11.17K64289.85K153.5K2.56K
Interest Expense00000
Other Income / Expenses10.34M822.67K849.14K845.5K726.84K
Income Before Tax(13.34M)(17.55M)(8.37M)(6.17M)(7.18M)
Pre-Tax Margin—————
Income Tax Expense800800800800800
Net Income(13.34M)(17.55M)(8.37M)(6.17M)(7.19M)
Net Margin—————
EPS (Basic)(7.74)(8.37)(2.93)(1.93)(1.27)
EPS (Diluted)(7.73)(8.37)(2.93)(1.93)(1.27)
Weighted Avg Shares1.73M2.1M2.86M3.2M5.68M
Weighted Avg Shares (Diluted)1.73M2.1M2.86M3.2M5.68M

Edesa Biotech, Inc.

NASDAQ:EDSA

Intrinsic Alpha fair value

Locked

Current Price

$5.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.